Chris Boshoff: The European Medicines Agency approved our Prostate Cancer combination for men living with metastatic castration-resistant prostate cancer

Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared on LinkedIn:

“I’m proud to share that today, the European Medicines Agency approved our Prostate Cancer combination for men living with metastatic castration-resistant prostate cancer, the most advanced, aggressive form of this disease.

Prostate cancer is the most frequently occurring cancer in men in Europe. With this approval, we are pleased to be able to offer a new treatment option for patients in Europe and expand our commitment to advance care for prostate cancer globally.”

Read further.
Proceed to the video attached to the post.
Source: Chris Boshoff/LinkedIn